Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
Glucagon was granted FDA approval on 14 November 1960.
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism
- Conditions
- Diabetes After Total Pancreatectomy
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT02944110
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02937558
- Locations
- 🇺🇸
UCSF School of Medicine, Division of Pediatric Endocrinology, San Francisco, California, United States
🇺🇸Washington University, St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸UCLA Mattel Children's Hospital, Los Angeles, California, United States
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 38
- Registration Number
- NCT02916251
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Drug: Insulin glulisine (U300)Drug: NPH insulin
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT02882737
- Locations
- 🇩🇰
Isabelle Steineck, Hvidovre, Denmark
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Other: 15-week intervention with sensor-augmented pumpOther: 15-week intervention with single-hormone closed-loopOther: 15-week intervention with dual-hormone closed-loopDevice: Insulin pumpDevice: Continuous glucose monitoring system
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Registration Number
- NCT02846857
To Determine Tolerability to Glucagon Infusion in Obese Subjects
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02817659
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02806960
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT02806973
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2
- Conditions
- Type 1 Diabetes
- Interventions
- Other: Dual-hormone closed-loopDevice: Dexcom G4 Platinum glucose sensorDevice: Accu Chek Combo insulin pump
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Target Recruit Count
- 11
- Registration Number
- NCT02798250
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.